Medical and economic impact of anemia in hospitalized patients

American Journal of Health-System Pharmacy

Volumn 64, Issue 16 SUPPL., 2007, Pages

  Spence, Richard K ^a  

^a Infonalé   (United States)

Author keywords

Anemia; Critical illness; Diagnosis; Economics; Hospitals; Mortality; Neoplasms

Indexed keywords

HEMOGLOBIN;

ANEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; DRUG EFFICACY; ECONOMIC ASPECT; ERYTHROCYTE TRANSFUSION; HEART LEFT VENTRICLE FAILURE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MORBIDITY; MORTALITY; ONCOLOGY; OXYGENATION; PHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

EID: 34547888014     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070244     Document Type: Conference Paper

References (54)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91:1616-34.
2. National Center for Health Statistics. FASTATS-Anemia. National Center for Health Statistics. www.cdc.gov/nchs/fastats/anemia.htm (accessed 2007 Jan10).
3. Ania BJ, Suman VJ, Fairbanks VF et al. Incidence of anemia in older people: an epidemiologic study in a well-defined population. J Am Geriatr Soc. 1997; 45:825-31.
4. Siciliano M, Tomasella D, Milani A et al. Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia. Hepatology. 1995; 22:1132-5.
5. Baer AN, Dessypris EN, Krantz SB. The pathogenesis of anemia in rheumatoid arthritis: a clinical and laboratory analysis. Semin Arthritis Rheum. 1990; 19:209-23.
6. Halm EA, Wang JJ, Boockvar K et al. The effect of perioperative anemia on clinical and functional outcomes in patients with hip fracture. J Orthop Trauma. 2004; 18:369-74.
7. Afzali B, Al-Khoury S, Shah N et al. Anemia after renal transplantation. Am J Kidney Dis. 2006; 48:519-36.
8. Mix TC, Kazmi W, Khan S et al. Anemia: a continuing problem following kidney transplantation. Am J Transplant. 2003; 3:1426-33.
9. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004; 116(Suppl 7A):11S-26S.
10. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005; 352:1011-23.
11. Lewis JD, Shin EJ, Metz DC. Characterization of gastrointestinal bleeding in severely ill hospitalized patients. Crit Care Med. 2000; 28:46-50.
12. Lanas A, Bajador E, Serrano P et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000; 343:834-9.
13. von Ahsen N, Muller C, Serke S et al. Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med. 1999; 27:2630-9.
14. Thavendiranathan P, Bagai A, Ebidia A et al. Do blood tests cause anemia in hospitalized patients? The effect of diagnostic phlebotomy on hemoglobin and hematocrit levels. J Gen Intern Med. 2005; 20:520-4.
15. Myers E, Grady PO, Dolan AM. The influence of preclinical anaemia on outcome following total hip replacement. Arch Orthop Trauma Surg. 2004; 124:699-701.
16. Munstedt K, Volzing M, Von Georgi R. Hemoglobin levels during radiation therapy and their influence on local control and survival of patients with endometrial carcinoma. Oncol Rep. 2004; 11:711-7.
17. Cho EI, Sasaki CT, Haffty BG. Prognostic significance of pretreatment hemoglobin for local control and overall survival in T1-T2N0 larynx cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2004; 58:1135-40.
18. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol. 2003; 41:1933-9.
19. Szachniewicz J, Petruk-Kowalczyk J, Majda J et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol. 2003; 90:303-8.
20. Spence RK. Anemia in the patient undergoing surgery and the transfusion decision. Clin Orthop Rel Res. 1998; 357:19-29.
21. Lundsgaard-Hansen P. Safe hemoglobin or hematocrit levels in surgical patients. World J Surg. 1996; 20:1182-8.
22. Yu M, Takanishi D, Myers SA et al. Frequency of mortality and myocardial infarction during maximizing oxygen delivery: A prospective, randomized trial. Crit Care Med. 1995; 23:1025-32.
23. Greenberg AG. A physiologic basis for red blood cell transfusion decisions. Am J Surg. 1995; 170(Suppl):44S-8S.
24. Wu SC, Rathore SS, Wang Y et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001; 345:1230-6.
25. Rao SV, Jollis JG, Harrington RA et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004; 292:1555-62.
26. Hébert PC, Wells G, Tweeddale M et al. Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group. Am J Respir Crit Care Med. 1997; 155:1618-23.
27. Labovich TM. Transfusion therapy. Clin J Oncol. 1997; 1:61-72.
28. Crosson JT. Massive transfusion. Clin Lab Med. 1996; 16:873-82.
29. Sloop GD, Friedberg RC. Complications of blood transfusion: How to recognize and respond to noninfectious reactions. Postgrad Med. 1995; 98:159-62, 166, 169-72.
30. Coffland FI, Shelton DM. Blood component replacement therapy. Crit Care Clin. 1993; 5:543-56.
31. Walter-Coleman S. Transfusion therapy for patients critically ill with cancer. AACN Clin Issues. 1996; 7:37-45.
32. Hill GE, Frawley WH, Griffith KE et al. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J. Trauma. 2003; 54:908-14.
33. Taylor RW, Manganaro L, O'Brien J et al. Impact of allogeneic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med. 2002; 30:2249-54.
34. Goodnough LT, Monk TG, Brecher ME. Acute normovolemic hemodilution should replace the preoperative donation of autologous blood as a method of autologous-blood procurement. Transfusion. 1998; 38:473-6.
35. Roberts WA, Kirkley SA, Newby M. A cost comparison of allogeneic and preoperatively or intraoperatively donated autologous blood. Anesth Analg. 1996; 83:129-33.
36. Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion. 2003; 43:668-76.
37. Food and Drug Administration Center for Drug Administration and Research. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA) FDA Alert [3/09/2007]. www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm (accessed 2007 Apr 17).
38. Danish Head and Neck Cancer Group. Interim analysis of DAHANCA 10: Study of the importance of novel erythropoiesis stimulating protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck. frejacms.au.dk/dahanca/get_media_file.pdf (accessed 2007 Apr 17).
39. Results from a phase 3, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy. www.clinicalstudyresults.org/ documents/company-study_2155 7_0.pdf (accessed 2007 Apr 17).
40. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007; 25:1027-32.
41. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly non-anemia patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005; 23:5960-72.
42. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355:2085-98.
43. Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355:2071-84.
44. Hebert PC, Wells G, Blajchman MA et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340:409-17.
45. Hebert PC, Yetisir E, Martin C et al. Is a low transfusion threshold safe in patients with cardiovascular disease? Crit Care Med. 2001; 29:227-34.
46. Nissenson AR, Wade S, Goodnough T et al. Economic burden of anemia in an insured population. J Manag Care Pharm. 2005; 11(7):565-74.
47. COBCON group of the Society for the Advancement of Blood Management. The cost of blood: Multidisciplinary conference for a standard methodology. Transfus Med Rev. 2005; 19:66-78.
48. Cantor SB, Hudson Jr DV, Lichtiger B et al. Costs of blood transfusion: A process-flow analysis. J Clin Oncol. 1998; 16:2364-70.
49. Crémieux PY, Barrett B, Anderson K et al. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol. 2000; 18:2755-61.
50. Forbes JM, Anderson MD, Anderson GF et al. Blood transfusion costs: A multi-center study. Transfusion. 1991; 31:318-23.
51. Lubarsky DA, Hahn C, Bennett DH et al. The hospital cost (fiscal year 1991/1992) of a simple perioperative allogeneic red blood cell transfusion during elective surgery at Duke University. Anesth Analg. 1994; 79:629-37.
52. Tretiak R, Laupacis A, Riviere M et al. Cost of allogeneic and autologous blood transfusion in Canada. Canadian Cost of Transfusion Study Group. CMAJ. 1996; 154:1501-8.
53. Varney SJ, Guest JF. The annual cost of blood transfusions in the UK. Transfus Med. 2003; 13:205-18.
54. Carson JL, Altman DG, Duff A et al. Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion. 1999; 39:694-700.